Gitterman Wealth Management LLC Purchases Shares of 621 Bio-Rad Laboratories, Inc. (NYSE:BIO)

Gitterman Wealth Management LLC purchased a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) during the fourth quarter, Holdings Channel reports. The institutional investor purchased 621 shares of the medical research company’s stock, valued at approximately $204,000.

A number of other hedge funds also recently bought and sold shares of BIO. Venturi Wealth Management LLC raised its position in Bio-Rad Laboratories by 2,175.0% in the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 87 shares in the last quarter. Gladius Capital Management LP acquired a new stake in Bio-Rad Laboratories in the 3rd quarter valued at about $32,000. Picton Mahoney Asset Management raised its position in Bio-Rad Laboratories by 55.6% in the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 35 shares in the last quarter. Asset Planning Inc acquired a new stake in Bio-Rad Laboratories in the 4th quarter valued at about $33,000. Finally, UMB Bank n.a. raised its position in Bio-Rad Laboratories by 41.6% in the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 32 shares in the last quarter. Institutional investors and hedge funds own 65.24% of the company’s stock.

Bio-Rad Laboratories Trading Up 4.2 %

NYSE:BIO opened at $255.34 on Friday. The stock’s 50 day moving average price is $311.97 and its 200 day moving average price is $328.01. The company has a market capitalization of $7.15 billion, a PE ratio of -3.93 and a beta of 0.99. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 52-week low of $244.00 and a 52-week high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. On average, research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on BIO shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $481.00 price objective on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. StockNews.com downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Finally, Wells Fargo & Company dropped their price objective on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 12th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $395.20.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.